Diagnostics

The role of lipid metabolism in Parkinson’s disease 2:18
The role of lipid metabolism in Parkinson’s disease
Serge Przedborski • 16 Sep 2022
The utility of genetic testing in the management of hyperkinetic movement disorders 3:47
The utility of genetic testing in the management of hyperkinetic movement disorders
Marcelo Kauffman • 17 Sep 2022
Novel a-syn PET tracer shows promise for diagnosis and monitoring in synucleinopathies 7:46
Novel a-syn PET tracer shows promise for diagnosis and monitoring in synucleinopathies
Francesca Capotosti • 2 Sep 2022
The promise of 4R tau-PET tracer development 1:06
The promise of 4R tau-PET tracer development
Francesca Capotosti • 2 Sep 2022
Recognizing iatrogenic movement disorders 1:58
Recognizing iatrogenic movement disorders
Carlo Colosimo • 16 Sep 2022
Is the clinical phenomenologist obsolete in movement disorders? 2:22
Is the clinical phenomenologist obsolete in movement disorders?
Kailash Bhatia • 16 Sep 2022
Functional imaging and tau PET tracers for diagnosing PSP & CBD 2:19
Functional imaging and tau PET tracers for diagnosing PSP & CBD
Rodolfo Savica • 16 Sep 2022
α-synuclein seed amplification assay for diagnosing Parkinson’s disease 1:02
α-synuclein seed amplification assay for diagnosing Parkinson’s disease
Tiago Outeiro • 17 Sep 2022
Assessment of functional movement disorders 2:25
Assessment of functional movement disorders
Alberto Espay • 16 Sep 2022
Advances in genetic testing in epilepsy 2:32
Advances in genetic testing in epilepsy
Challenges surrounding the implementation of genetic diagnosis in daily practice settings 4:53
Challenges surrounding the implementation of genetic diagnosis in daily practice settings
Heather Olson • 28 Mar 2022
Should patients with a single unprovoked seizure be evaluated and treated as if they have epilepsy? 7:11
Should patients with a single unprovoked seizure be evaluated and treated as if they have epilepsy?
Anteneh Feyissa • 25 Mar 2022
Huntington’s disease integrated staging system (HD-ISS) for clinical research 1:46
Huntington’s disease integrated staging system (HD-ISS) for clinical research
Jee Bang • 4 Apr 2022
Defining spinal cord reserve and its correlation with disability in MS 4:16
Defining spinal cord reserve and its correlation with disability in MS
Jaume Sastre-Garriga • 3 Apr 2022
Developments in utilizing MRI biomarkers in MS 3:07
Developments in utilizing MRI biomarkers in MS
Jaume Sastre-Garriga • 3 Apr 2022
Utility of brain volumetry and tissue integrity in MS diagnosis 2:29
Utility of brain volumetry and tissue integrity in MS diagnosis
Jaume Sastre-Garriga • 3 Apr 2022
The content of VJNeurology is intended for healthcare professionals